Literature DB >> 9927818

[Therapeutic evaluation of artesunate in experimental Schistosoma mansoni infection].

N Araújo1, A Kohn, N Katz.   

Abstract

Mice experimentally infected with Schistosoma mansoni were treated orally with artesunate (Lactab) in a single dose of 300 or 500 mg/kg or over a period of five consecutive days. The animals were sacrificed 7, 30, 60 or 90 days after treatment. Statistically significant differences were found in the distribution and mortality of the worms and in the alterations of the oogram in the treated group when compared to control in all of the tested schemes when the animals were sacrificed 30 days after treatment. Morphological analysis of female worms showed a reduction of ovarian volume and rarefaction of the vitelline follicles. These modifications were more marked after treatment with the higher dose, explaining the alteration of the oogram which reached 100%. However, when the animals were sacrificed 60 or 90 days after treatment, the differences and alterations were smaller, showing that the surviving worms recovered and restarted oviposition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927818

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  3 in total

1.  Artemisinin: the gifts from traditional Chinese medicine not only for malaria control but also for schistosomiasis control.

Authors:  Rong Liu; Hui-Fen Dong; Ming-Sen Jiang
Journal:  Parasitol Res       Date:  2011-10-27       Impact factor: 2.289

2.  Evaluation of Artesunate and Praziquantel Combination Therapy in Murine Schistosomiasis mansoni.

Authors:  Laila Abdel Moniem Hegazy; Mona Hussein Al Motiam; Naglaa Fathy Abd El-Aal; Shereen Mahmoud Ibrahim; Heba Khalil Mohamed
Journal:  Iran J Parasitol       Date:  2018 Apr-Jun       Impact factor: 1.012

3.  Schistogram changes after administration of antischistosomal drugs in mice at the early phase of Schistosoma mansoni infection.

Authors:  Andréa Cássia Simões Vimieiro; Neusa Araújo; Naftale Katz; John Robert Kusel; Paulo Marcos Zech Coelho
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.